New drug TJ0113 passes first safety check in healthy volunteers
NCT ID NCT07394452
First seen Feb 06, 2026 · Last updated May 01, 2026 · Updated 10 times
Summary
This early-stage study tested TJ0113 capsules in 130 healthy adults to see if they are safe and how the body processes them. Participants took single or multiple doses, and some took the drug after a high-fat meal. The main goal was to track any side effects and measure drug levels in the blood.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY SUBJECTS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Zhejiang Xiaoshan hospital
Hangzhou, Zhejiang, 310009, China
Conditions
Explore the condition pages connected to this study.